C.F.M.

CFM Pharma is a Dutch clinical-stage biotechnology company focused on developing innovative tissue protection and regeneration therapies for acute traumatic injuries. The company's core technology is the VANADIS platform, which utilizes proprietary organovanadium compounds to modulate multi-pathway mechanisms, including the inhibition of protein tyrosine phosphatases (PTPs) to enhance pro-angiogenic signaling. Its lead candidate, VANADIS BMOV, is being developed for the treatment of myocardial infarction to reduce infarct size and improve cardiac recovery. Additionally, CFM Pharma is advancing programs for severe burns and acute kidney injury, leveraging its tissue-repair technology to address significant unmet needs in acute care medicine.